DOCSLIB.ORG

Improved and Efficient Therapy of Acromegaly by Implementation of a Personalized and Predictive Algorithm Including Molecular and Clinical Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Improved and Efficient Therapy of Acromegaly by Implementation of a Personalized and Predictive Algorithm Including Molecular and Clinical Information ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Improved and efficient therapy of acromegaly by implementation of a personalized and predictive algorithm including molecular and clinical information PhD thesis by: Joan Gil Ortega Thesis supervisors: Prof. Manel Puig Domingo Dr. Mireia Jordà Ramos Tutor: Prof. Manel Puig Domingo Doctoral Program in Medicine. Department of Medicine. 2020 Acknowledgments M’agradaria agrair amb aquestes línies a les persones que han fet possible aquesta tesis, tant directament com indirectament. D’aquest període de la meva vida m’emporto moltes i bones experiències, grans aprenentatges i fins i tot, alguna nova habilitat. Però les persones que he trobat i m’han acompanyat durant aquests anys han estat el més important al·licient i el principal record que m’enduc d’aquests anys. I si parlem de persones no puc evitar anomenar, per contradictori que sembli, una institució, l’IGTP i l’antic IMPPC. On la primera persona que vaig conèixer va ser la meva directora de tesi Mireia Jordà que m’ha guiat durant tot aquest procés amb passió i dedicació. També vull agrair al Prof. Manel Puig per deixar-me participar en aquesta recerca tant captivadora en una malaltia tan interessant. A més a més, al IGTP he fet grans amics que sé que m’acompanyaran durant uns quants anys després d’aquesta experiència. He d’agrair a la gent del EiN les hores compartides a la Núria, la meva mestra en el laboratori, a la Bea, la Mireia, l’Helena, la Irene i tota la resta d’estudiants que han anant desfilant i que espero que els he ensenyat hagi estat profitós (especialment les minions Anna i Melania). A la gent del MAPlab i aniling, en especial a la Júlia, la Mar i la Berta per l’ajuda en moment crítics. També a les persones que he conegut dinant i que hem compartit molts dies i moltes històries, en Roberto, l’Emili, l’Izaskun, la Natàlia... Els qui m’han transmès l’amor per la bicicleta: l’Iñaki, en Sergio, en Lloyd i la Tanya amb el seu taller. I com no agrair als tres mosqueters: Edu, Laura i Marc els bons moments viscuts, molts que s’han gaudit i patit alhora. A la gent d’escalada: la Carme i la Marta. I fora de la recerca he d’agrair a la gent de la música també el suportar-me en molts moments. A les nenes del conservatori: la Vero, la Luisa, l’Ana i la Glòria. A l’Òria per fer-me de psicòloga de tant en tant. I a la meva estimada JOC que ha vegades m’ha fet anar més de cul que una altra cosa però que molts cops ha estat necessària. També voldria agrair a la meva família el seu suport en tot moment malgrat les vicissituds viscudes, en especial a la meva mare ja que aguantar a un fill fent el doctorat no és fàcil i els meus avis. Als meus professors de tots aquests anys, especialment a en Pep Lloreta, i a la gent del PRBB. I finalment, als amics de la UPF que alguns ja han passat pel tràngol del doctorat en especial a la Natàlia i a la Mónica. Moltes gràcies a tots. 1 Abbreviations ACC accuracy ACTH adrenocorticotropic hormone; also adrenocorticotropin or corticotropin AIP aryl hydrocarbon receptor interacting protein ARRB1 arrestin-beta 1 ARRB2 arrestin-beta 2 ATG autogel AUC area under the curve BMI body mass index cAMP cyclic adenosine monophosphate CDH1 E-cadherin; cadherin 1 CDH2 N-cadherin; cadherin 2 cDNA complementary DNA CI confidence interval CpG cytosine nucleotide is followed by a guanine nucleotide in the linear sequence CR complete responders to SRLs chorionic somatomammotropin hormone 1; also known as human placental CSH1 lactogen CSH2 chorionic somatomammotropin hormone 2 CSHL1 chorionic somatomammotropin hormone like 1 CV coefficient of variation DA dopamine agonists DNA deoxyribonucleic acid DRD1 dopamine receptor D1 DRD2 dopamine receptor D2 DRD5 dopamine receptor D5 EMT epithelial-mesenchymal transition ERK1 mitogen-activated protein kinase 3, extracellular signal-regulated kinase 1 ERK2 mitogen-activated protein kinase 1, extracellular signal-regulated kinase 2 ESRP1 epithelial splicing regulator 1 FC fold change 2 FFAs free fatty acids FIPA familial isolated pituitary adenoma FSH follicle-stimulating hormone GH growth hormone or somatotropin GH1 growth hormone 1; pituitary growth hormone GH2 growth hormone 2 GHR growth hormone receptor GHRH growth hormone-releasing hormone, also known as somatocrinin GHRHR growth-hormone-releasing hormone receptor GHRL ghrelin GHSR1a growth hormone secretagogue receptor 1A guanine nucleotide binding protein (G protein), alpha stimulating activity GNAS polypeptide 1 GUSB glucuronidase beta HBP high blood pressure HPRT1 hypoxanthine phosphoribosyl transferase 1 IGF-1 insulin-like growth factor 1, also called somatomedin C IHC immunohistochemistry In1-GHRL intron 1 ghrelin IRS-1 insulin receptor substrate 1 JAK2 Janus kinase 2 KLK10 kallikrein 10 LAR long acting release LH luteinizing hormone, also known as lutropin MAPK Mitogen-Activated Protein Kinases MEK Dual specificity mitogen-activated protein kinase kinase miRNA micro RNAs MRI magnetic resonance imaging MRPL19 mitochondrial ribosomal protein L19 MSH melanocyte stimulating hormone NeuroD4 neuronal differentiation 4 NR non-responders to SRLs OGTT oral glucose tolerance test OR odds ratio 3 PCR polymerase chain reaction phosphatidylethanolamine binding protein 1, also known as raf kinase inhibitory PEBPB1 protein PEG polyethylene glycol PGK1 phosphoglycerate kinase 1 pituitary-specific positive transcription factor 1; POU domain, class 1, transcription Pit1 factor 1 PLAGL1 pleiomorphic adenoma gene-like 1, also known as zinc finger 1 (ZAC1) PR partial responders to SRLs PRL prolactin, also known as lactotropin PSMC4 proteasome 26S subunit ATPase 4 qPCR quantitative polymerase chain reactions, also known as real time PCR REMAH Registro Molecular de Adenomas Hipofisarios phosphatidylethanolamine binding protein 1, also known as raf kinase inhibitory RKIP protein RNA ribonucleic acid ROC receiver operating characteristic RORC retinoic acid-related orphan receptor C RT-qPCR reverse trancription Qpcr SD standard deviation SDS standard deviation score SLRs somatostatin receptor ligands SNAI1 snail family transcriptional repressor 1 SNAI2 snail family transcriptional repressor 2 SRIF somatostatin; somatotropin release-inhibiting factor SST somatostatin sst5TMD4 splicing variant of SSTR5 with 4 transmembrane domains sst5TMD5 splicing variant of SSTR5 with 5 transmembrane domains SSTR1 somatostatin receptor 1 SSTR2 somatostatin receptor 2 SSTR3 somatostatin receptor 3 SSTR4 somatostatin receptor 4 SSTR5 somatostatin receptor 5 SSTRs somatostatin receptors 4 STAT1 signal transducer and activator of transcription 1 STAT5 signal transducer and activator of transcription 5 TBP TATA-Box Binding Protein TGF-β transforming growth factor beta TSH thyroid-stimulating hormone, also known as thyrotropin TWIST1 twist family bHLH transcription factor 1 VIM vimentin VIP secretin; vasoactive intestinal peptide 5 Contents Section Page Acknowledgments 1 Abbreviations 2 Abstract 8 Resum 9 1. Introduction 10 1.1 The Pituitary Gland 10 1.1.1 Anatomy and histology 10 1.1.2 Somatotroph cells and growth hormone 11 1.1.3 GH regulation 11 1.1.4 Peripheral GH actions 13 1.2 Acromegaly 14 1.2.1 History of acromegaly 14 1.2.2 Epidemiology 14 1.2.3 Pathogenesis 15 1.2.4 Diagnosis 16 1.2.5 Clinical Manifestations 17 1.3 Treatment of Acromegaly 18 1.3.1 Surgery 18 1.3.2 Radiation treatment 19 1.3.3 Dopamine agonist 19 1.3.4 Somatostatin receptor ligands (SRLs) 19 1.3.5 Pegvisomant 21 1.3.6 Choice of therapy 22 1.4 Clinical and molecular predictors to medical therapy response 23 1.5 Personalized medicine in acromegaly 27 2. Hypotheses 29 3. Objectives 30 4. Material and methods 31 4.1 Patients 32 4.2 Biochemical and hormonal assays 32 4.3 Bioethical statement 33 4.4 DNA and RNA isolation 33 4.5 Retrotranscription 33 4.6 Quantitative polymerase chain reaction 33 4.6 GNAS sequencing 35 4.7 E-cadherin promoter methylation assessment 35 4.8 Standard Statistical Analysis 38 4.9 Data mining analyses 39 5. Results 45 5.1 Study 1: Molecular profiling for acromegaly treatment: a validation study 46 5.2 Study 2: Association of Epithelial-mensenchymal transition (EMT) markers with response to somatostatin receptor ligands 6 in GH-secreting tumors 58 5.3 Study 3: Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH producing adenomas 66 5.4 Study 4: Data mining analyses for precision medicine in acromegaly 72 6. Discussion 81 7. Conclusions 91 8. Future perspective 92 9. Bibliography 95 10. Annex 118 10.1 Supplementary Tables 118 10.2 Supplementary Figures 122 7 Abstract Actual pharmacologic treatment in acromegaly is currently based upon assay-error strategy. The prompt biochemical control of the disease is essential to reduces comorbidities and mortality. Fortunately, several drugs have been developed over the years to treat acromegaly being first generation somatostatin receptor ligands (SRLs), the first-line treatment. However, up to 50% of patients do not respond adequately to SRLs, which delays biochemical control for months or even a year. The main objective of this thesis was to evaluate the potential usefulness of different molecular markers as predictors of response to SRLs and elaborate a new treatment algorithm accordingly. We taught advantage of the REMAH cohort of several nodes in Spain to collect 100 acromegaly samples and performed molecular analysis.
Load more

Recommended publications
  • Feedback Regulation of Growth Hormone Synthesis and Secretion in Fish and the Emerging Concept of Intrapituitary Feedback Loop ☆ ⁎ Anderson O.L
    http://www.paper.edu.cn Comparative Biochemistry and Physiology, Part A 144 (2006) 284–305 Review Feedback regulation of growth hormone synthesis and secretion in fish and the emerging concept of intrapituitary feedback loop ☆ ⁎ Anderson O.L. Wong , Hong Zhou, Yonghua Jiang, Wendy K.W. Ko Department of Zoology, University of Hong Kong, Pokfulam Road, Hong Kong, P.R. China Received 29 July 2005; received in revised form 21 November 2005; accepted 21 November 2005 Available online 9 January 2006 Abstract Growth hormone (GH) is known to play a key role in the regulation of body growth and metabolism. Similar to mammals, GH secretion in fish is under the control of hypothalamic factors. Besides, signals generated within the pituitary and/or from peripheral tissues/organs can also exert a feedback control on GH release by effects acting on both the hypothalamus and/or anterior pituitary. Among these feedback signals, the functional role of IGF is well conserved from fish to mammals. In contrast, the effects of steroids and thyroid hormones are more variable and appear to be species-specific. Recently, a novel intrapituitary feedback loop regulating GH release and GH gene expression has been identified in fish. This feedback loop has three functional components: (i) LH induction of GH release from somatotrophs, (ii) amplification of GH secretion by GH autoregulation in somatotrophs, and (iii) GH feedback inhibition of LH release from neighboring gonadotrophs. In this article, the mechanisms for feedback control of GH synthesis and secretion are reviewed and functional implications of this local feedback loop are discussed. This intrapituitary feedback loop may represent a new facet of pituitary research with potential applications in aquaculture and clinical studies.
    [Show full text]
  • Alternative Processing of Bovine Growth Hormone Mrna
    Proc. Natl. Acad. Sci. USA Vol. 84, pp. 2673-2677, May 1987 Biochemistry Alternative processing of bovine growth hormone mRNA: Nonsplicing of the final intron predicts a high molecular weight variant of bovine growth hormone (intron D/alternative reading frame/growth hormone-related polypeptide) ROBERT K. HAMPSON AND FRITZ M. ROTTMAN Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, 2119 Abington Road, Cleveland, OH 44106 Communicated by Lester 0. Krampitz, January 2, 1987 (received for review September 10, 1986) ABSTRACT We have detected a variant species of bovine MATERIALS AND METHODS growth hormone mRNA in bovine pituitary tissue and in a stably transfected bovine growth hormone-producing cell line. CHO 14-10-4 Cell Line. The Chinese hamster ovary (CHO) Analysis of this variant mRNA indicated that the last inter- cell line, CHO 14-10-4, utilized in these studies was gener- vening sequence (intron D) had not been removed by splicing. ously provided by Leonard Post. These cells were derived Inspection of the sequence of intron D reveals an open reading frame through the entire intron, with a termination codon from the DBX-11 cell line of dihydrofolate reductase-nega- encountered 50 nucleotides into the fifth exon, which is shifted tive CHO cells (6) and have been stably transfected with an from the normal reading frame in this variant mRNA. If expression plasmid containing the bovine growth hormone translated, this variant mRNA would encode a growth hor- gene. This expression plasmid, pSV2Cdhfr (Fig. 1), contains mone-related polypeptide having 125 amino-terminal amino the BamHI/EcoRI fragment of the bovine growth hormone acids identical to wild-type growth hormone, followed by 108 genomic clone (2) in the plasmid pSV2dhfr (7) situated carboxyl-terminal amino acids encoded by the 274 bases of downstream from a 760-base-pair Sau3A fragment containing intron D along with the first 50 nucleotides of exon 5.
    [Show full text]
  • Download?Doi=10.1.1.640.8406&Rep=Rep1&T Ype=Pdf
    UC Riverside UC Riverside Electronic Theses and Dissertations Title The Effects of Temperature, Salinity, and Bifenthrin on the Behavior and Neuroendocrinology of Juvenile Salmon and Trout Permalink https://escholarship.org/uc/item/9jv04705 Author Giroux, Marissa Sarah Publication Date 2019 License https://creativecommons.org/licenses/by-nd/4.0/ 4.0 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA RIVERSIDE The Effects of Temperature, Salinity, and Bifenthrin on the Behavior and Neuroendocrinology of Juvenile Salmon and Trout A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Environmental Toxicology by Marissa S. Giroux June 2019 Dissertation Committee: Dr. Daniel Schlenk, Chairperson Dr. David Volz Dr. Andrew Gray Copyright by Marissa S. Giroux 2019 The Dissertation of Marissa S. Giroux is approved: Committee Chairperson University of California, Riverside ACKNOWLEDGEMENTS Without the support, guidance, training, and time of many people this dissertation would not be possible. First, I would like to thank my Advisor, Dr. Daniel Schlenk for his help in in applying for fellowships, guidance in experimental design, taking the time to help me network, and giving me the opportunity to teach and mentor in both the lab and classroom. I would also like to thank my committee members, Dr. David Volz and Dr. Andrew Gray, for their wonderful recommendations and advice throughout my years at UC-Riverside. I have immense gratitude for my lab family, both past and present, who trained me, supported me, and taught me all of the “other” things you learn in grad school.
    [Show full text]
  • Growth Hormone Therapy in Children with Chronic Renal Failure
    Eurasian J Med 2015; 47: 62-5 Review Growth Hormone Therapy in Children with Chronic Renal Failure Kronik Böbrek Yetmezliği olan Çocuklarda Büyüme Hormonu Tedavisi Atilla Cayir1, Celalettin Kosan2 1Department of Pediatric Endocrinology, Regional Training and Research Hospital, Erzurum, Turkey 2Department of Pediatric Nephrology, Ataturk University Faculty of Medicine, Erzurum, Turkey Abstract Özet Growth is impaired in a chronic renal failure. Anemia, acidosis, re- Kronik böbrek yetersizliğinde büyüme bozulmaktadır. Anemi, asidoz, duced intake of calories and protein, decreased synthesis of vitamin kalori ve protein alımının azalması, azalmış vitamin D sentezi ve artmış D and increased parathyroid hormone levels, hyperphosphatemia, parathormon düzeyi, hiperfosfatemi, renal osteodistrofi ve büyüme renal osteodystrophy and changes in growth hormone-insulin-like hormonu, insülin benzeri growth faktör ile gonadotropin- gonadal growth factor and the gonadotropin-gonadal axis are implicated in akstaki değişiklikler büyümenin yetersiz olmasından sorumlu tutul- this study. Growth is adversely affected by immunosuppressives and maktadır. Böbrek transplantasyonundan sonra ise immunosupressifler corticosteroids after kidney transplantation. Treating metabolic dis- ve kortikosteroidlerin etkileri ile büyüme olumsuz olarak etkilenmek- orders using the recombinant human growth hormone is an effective tedir. Metabolik bozuklukların düzeltilmesine rağmen büyüme hızı option for patients with inadequate growth rates. yetersiz olan olgularda rekombinant insan büyüme hormonu iyi bir Keywords: Child, chronic renal failure, growth hormone, therapy tedavi seçeneğidir. Anahtar Kelimeler: Çocuk, kronik böbrek yetersizliği, büyüme hor- monu, tedavi Introduction mone takes place with glomerular filtration and breakdown in the proximal tubules. In CRF, a decrease in the rate of glo- Inadequate growth is a widespread problem in children merular filtration leads to impairment of the metabolic clear- with chronic renal failure (CRF).
    [Show full text]
  • A Bioinformatics Model of Human Diseases on the Basis Of
    SUPPLEMENTARY MATERIALS A Bioinformatics Model of Human Diseases on the basis of Differentially Expressed Genes (of Domestic versus Wild Animals) That Are Orthologs of Human Genes Associated with Reproductive-Potential Changes Vasiliev1,2 G, Chadaeva2 I, Rasskazov2 D, Ponomarenko2 P, Sharypova2 E, Drachkova2 I, Bogomolov2 A, Savinkova2 L, Ponomarenko2,* M, Kolchanov2 N, Osadchuk2 A, Oshchepkov2 D, Osadchuk2 L 1 Novosibirsk State University, Novosibirsk 630090, Russia; 2 Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russia; * Correspondence: [email protected]. Tel.: +7 (383) 363-4963 ext. 1311 (M.P.) Supplementary data on effects of the human gene underexpression or overexpression under this study on the reproductive potential Table S1. Effects of underexpression or overexpression of the human genes under this study on the reproductive potential according to our estimates [1-5]. ↓ ↑ Human Deficit ( ) Excess ( ) # Gene NSNP Effect on reproductive potential [Reference] ♂♀ NSNP Effect on reproductive potential [Reference] ♂♀ 1 increased risks of preeclampsia as one of the most challenging 1 ACKR1 ← increased risk of atherosclerosis and other coronary artery disease [9] ← [3] problems of modern obstetrics [8] 1 within a model of human diseases using Adcyap1-knockout mice, 3 in a model of human health using transgenic mice overexpressing 2 ADCYAP1 ← → [4] decreased fertility [10] [4] Adcyap1 within only pancreatic β-cells, ameliorated diabetes [11] 2 within a model of human diseases
    [Show full text]
  • Prevalence of Human Growth Hormone-1 Gene Deletions Among Patients with Isolated Growth Hormone Deficiency from Different Populations
    003 1-399819213105-0532$03.00/0 PEDIATRIC RESEARCH Vol. 3 1, No. 5, 1992 Copyright O 1992 international Pediatric Research Foundation, Inc. Prinled in U.S. A. Prevalence of Human Growth Hormone-1 Gene Deletions among Patients with Isolated Growth Hormone Deficiency from Different Populations P. E. MULLIS, A. AKINCI, CH. KANAKA, A. EBLE, AND C. G. D. BROOK Deparfment of Paediafrics, Inselspital, Bern, Switzerland [P.E.M.. Ch.K., A.E.]; Department of Paediatric Endocrinology, Dr. Sami Ulus Childrens Hospital, Ankara, Turkey [A.A.]; and Endocrine Unit, The Middlesex Hospital, London WIN 8AA. United Kingdom [C.G.D.B.] ABSTRACT. Familial isolated growth hormone deficiency suggested to be familial (2). Four distinct familial types of IGHD type IA results from homozygosity for either a 6.7-kb or a are well-differentiated on the basis of inheritance and other 7.6-kb hGH-1 gene deletion. Genomic DNA was extracted hormone deficiencies (3). One form is IGHD type IA, resulting from circulating lymphocytes of 78 subjects with severe from a GH-1 gene deletion (4, 5). Subjects with IGHD type IA isolated growth hormone deficiency (height < -4.5 SD may have short body length at birth and present occasionally score) and studied by polymerase chain amplification and with hypoglycemia, but severe growth retardation by 6 mo of by restriction endonuclease analysis looking for gene dele- age is a constant finding. Treatment with hGH is frequently tions within the hGH-gene cluster. The individuals ana- complicated by the development of anti-hGH antibodies in a lyzed were broadly grouped into three different populations titer sufficient to cause arrest ofresponse to the hGH replacement (North-European, n = 32; Mediterranean, n = 22; and (6).
    [Show full text]
  • The Fish Embryo As an Alternative Model for the Assessment of Endocrine Active Environmental Chemicals
    The fish embryo as an alternative model for the assessment of endocrine active environmental chemicals: Elucidation of endocrine disruptive mechanisms and identification of relevant effect endpoints using transcriptomics Von der Fakult¨atf¨ur Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades einer Doktorin der Naturwissenschaften genehmigte Dissertation vorgelegt von Diplom-Oecotrophologin Viktoria Schiller aus Simferopol (Ukraine) Berichter: Universit¨atsprofessorDr. Rainer Fischer Universit¨atsprofessorDr. Henner Hollert Universit¨atsprofessorDr. J¨orgOehlmann Tag der m¨undlichen Pr¨ufung:02.12.2013 Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek on- line verf¨ugbar. ii Contents Summary xv Zusammenfassung xviii 1 Introduction and objectives of the thesis1 1.1 Endocrine disruption in fish.................1 1.2 Endocrine disrupting chemicals in current regulation...3 1.3 Alternatives for endocrine disruption testing........5 1.4 Fundamental background of endocrine disruption.....8 1.4.1 Hypothalamic-pituitary-gonadal axis in fish....8 1.4.2 Mechanisms of endocrine disruption in brief.... 10 1.4.2.1 Receptor mediated signalling....... 12 1.4.2.2 Receptor-independent mechanisms.... 13 1.5 Key facts about zebrafish and medaka........... 13 1.5.1 Species- and embryo specific traits (or attributes). 15 1.5.1.1 Sexual differentiation of zebrafish and medaka 16 1.5.1.2 Role of aromatase in sex differentiation.. 17 1.5.1.3 Sex steroid receptors in fish embryos... 18 1.6 Objectives........................... 20 2 Material and methods 23 2.1 Fish maintenance and exposure............... 23 2.2 RNA extraction and reverse transcription.......... 25 2.3 Quantitative real-time PCR................. 26 2.4 Microarray analysis.....................
    [Show full text]
  • Effect of Different Growth Hormone (GH) Mutants on the Regulation Of
    European Journal of Endocrinology (2002) 146 573–581 ISSN 0804-4643 EXPERIMENTAL STUDY Effect of different growth hormone (GH) mutants on the regulation of GH-receptor gene transcription in a human hepatoma cell line Johnny Deladoe¨y, Gre´goire Gex, Jean-Marc Vuissoz, Christian J Strasburger1, Michael P Wajnrajch2 and Primus E Mullis Department of Paediatrics, Division of Paediatric Endocrinology, Inselspital, CH-3010 Bern, Switzerland, 1Medizinische Klinik-Innenstadt, Ludwig-Maximilians-Universita¨t, Munich, Germany and 2 Division of Paediatric Endocrinology, Weill Medical College of Cornell University, New York, NY, USA (Correspondence should be addressed to Primus E Mullis, University Children’s Hospital, Inselspital, CH-3010 Bern, Switzerland; Email: [email protected]) Abstract Objective: G to A transition at position 6664 of the growth hormone (GH-1 ) gene results in the substitution of Arg183 by His (R183H) in the GH protein and causes a new form of autosomal dominant isolated GH deficiency (IGHD type II). The aim of this study was to assess the bioactivity of this R183H mutant GH in comparison with both other GH variants and the 22-kDa GH in terms of GH-receptor gene regulation. Design and Methods: The regulation of the GH-receptor gene (GH-receptor/GH binding protein, GHR/GHBP) transcription following the addition of variable concentrations (0, 12.5, 25, 50 and 500 ng/ml) of R183H mutant GH was studied in a human hepatoma cell line (HuH7) cultured in a serum-free hormonally defined medium. In addition, identical experiments were performed using either recombinant human GH (22-kDa GH) as a positive control or two GH-receptor antagonists (R77C mutant GH and pegvisomant (B-2036-PEG)) as negative controls.
    [Show full text]
  • Views of the NIDA, NINDS Or the National Summed Across the Three Auditory Forebrain Lobule Sec- Institutes of Health
    Xie et al. BMC Biology 2010, 8:28 http://www.biomedcentral.com/1741-7007/8/28 RESEARCH ARTICLE Open Access The zebra finch neuropeptidome: prediction, detection and expression Fang Xie1, Sarah E London2,6, Bruce R Southey1,3, Suresh P Annangudi1,6, Andinet Amare1, Sandra L Rodriguez-Zas2,3,5, David F Clayton2,4,5,6, Jonathan V Sweedler1,2,5,6* Abstract Background: Among songbirds, the zebra finch (Taeniopygia guttata) is an excellent model system for investigating the neural mechanisms underlying complex behaviours such as vocal communication, learning and social interactions. Neuropeptides and peptide hormones are cell-to-cell signalling molecules known to mediate similar behaviours in other animals. However, in the zebra finch, this information is limited. With the newly-released zebra finch genome as a foundation, we combined bioinformatics, mass-spectrometry (MS)-enabled peptidomics and molecular techniques to identify the complete suite of neuropeptide prohormones and final peptide products and their distributions. Results: Complementary bioinformatic resources were integrated to survey the zebra finch genome, identifying 70 putative prohormones. Ninety peptides derived from 24 predicted prohormones were characterized using several MS platforms; tandem MS confirmed a majority of the sequences. Most of the peptides described here were not known in the zebra finch or other avian species, although homologous prohormones exist in the chicken genome. Among the zebra finch peptides discovered were several unique vasoactive intestinal and adenylate cyclase activating polypeptide 1 peptides created by cleavage at sites previously unreported in mammalian prohormones. MS-based profiling of brain areas required for singing detected 13 peptides within one brain nucleus, HVC; in situ hybridization detected 13 of the 15 prohormone genes examined within at least one major song control nucleus.
    [Show full text]
  • Growth Hormone [Somatropin]
    Cigna National Formulary Coverage Policy Prior Authorization Growth Disorders - Growth hormone [somatropin] Table of Contents Product Identifer(s) National Formulary Medical Necessity ................ 1 12988 Conditions Not Covered....................................... 8 Background ........................................................ 10 References ........................................................ 14 Revision History ................................................. 16 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
    HYPOTHESIS AND THEORY published: 28 January 2021 doi: 10.3389/fmed.2021.628029 Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Dominic Stanculescu 1, Lars Larsson 2 and Jonas Bergquist 3,4* 1 Independent Researcher, Sint Martens Latem, Belgium, 2 Basic and Clinical Muscle Biology, Department of Physiology and Pharmacology, Karolinska Institute, Solna, Sweden, 3 Analytical Chemistry and Neurochemistry, Department of Chemistry – Biomedical Center, Uppsala University, Uppsala, Sweden, 4 The Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centre at Uppsala University, Uppsala, Sweden Edited by: Here the hypothesis is advanced that maladaptive mechanisms that prevent Nuno Sepulveda, recovery in some intensive care unit (ICU) patients may also underlie Myalgic Charité–Universitätsmedizin Berlin, Germany encephalomyelitis/chronic fatigue syndrome (ME/CFS). Specifically, these mechanisms Reviewed by: are: (a) suppression of the pituitary gland’s pulsatile secretion of tropic hormones, and (b) Jose Alegre-Martin, a “vicious circle” between inflammation, oxidative and nitrosative stress (O&NS), and low Vall d’Hebron University thyroid hormone function. This hypothesis should be investigated through collaborative Hospital, Spain Klaus Wirth, research projects. Sanofi, Germany Jonathan Kerr, Keywords: myalgic encephalomyelitis, critical illness, non-thyroidal illness syndrome, low t-3 syndrome, pituitary, Norfolk and Norwich
    [Show full text]
  • GH1 Gene Growth Hormone 1
    GH1 gene growth hormone 1 Normal Function The GH1 gene provides instructions for making the growth hormone protein. Growth hormone is produced in the growth-stimulating somatotropic cells of the pituitary gland, which is located at the base of the brain. Growth hormone is necessary for the normal growth of the body's bones and tissues. The production of growth hormone is triggered when two other hormones are turned on (activated): ghrelin, which is produced in the stomach; and growth hormone releasing hormone, which is produced in a part of the brain called the hypothalamus. Ghrelin and growth hormone releasing hormone also stimulate the release of growth hormone from the pituitary gland. The release of growth hormone into the body peaks during puberty and reaches a low point at about age 55. Cells in the liver respond to growth hormone and trigger the production of a protein called insulin-like growth factor-I (IGF-I). This protein stimulates cell growth and cell maturation (differentiation) in many different tissues, including bone. The production of IGF-I by the actions of growth hormone is a major contributor to the promotion of growth. Growth hormone also plays a role in many chemical reactions (metabolic processes) in the body. By acting on specific tissues, growth hormone is involved in protein production and the breakdown (metabolism) of fats and carbohydrates. Health Conditions Related to Genetic Changes Isolated growth hormone deficiency More than 70 mutations in the GH1 gene have been found to cause isolated growth hormone deficiency, a condition characterized by slow growth and short stature.
    [Show full text]